cosagliptin

Cosagliptin is a novel, orally administered small molecule belonging to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. Developed by Haisco Pharmaceutical, its primary indication is for the improvement of glycemic control in adults with type 2 diabetes mellitus. The drug functions by inhibiting the DPP-4 enzyme, which in turn increases the circulating levels of active incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to enhanced glucose-dependent insulin secretion and suppressed glucagon release, ultimately resulting in reduced blood glucose levels. A notable feature of cosagliptin is its extended pharmacokinetic profile, allowing for a convenient bi-weekly (every 14 days) dosing regimen, which is expected to improve patient adherence. It has also been noted that cosagliptin does not require dose adjustment for patients with renal impairment.

Brand names

倍长平

Other names

考格列汀